Genetic association studies have identified polymorphism of LDL receptor-related protein-1 (LRP1) as a risk factor for metabolic diseases including premature atherosclerosis. This is a multi- functional receptor that serves as a cargo transporting endocytic receptor for numerous different ligands as well as a receptor with cell signaling properties in modulating cell functions. Results obtained during the past funding period showed LRP1 inactivation in adipocytes yielded animals that are resistant to diet- induced obesity and diabetes. However, the LRP1-deficient adipocytes are dysfunctional with elevated inflammatory gene expression. Our result also showed that liver-specific inactivation of LRP1 reduces HDL production, lowers plasma HDL-cholesterol levels, and promotes injury-induced steatohepatitis and liver cirrhosis. Taken together, these results indicate that LRP1 inactivation in adipose and liver promotes other metabolic disorders despite its protection against diet induced-obesity and diabetes. The latest data revealed LRP1 inactivation reduces lysosomal enzyme processing in both adipocytes and hepatocytes. The goal of this project is to test the overall hypothesis that LRP1 suppresses diet-induced tissue dysfunctions and inflammation and protects against injury-induced steatohepatitis via modulation of lysosomal enzyme sorting and receptor cell signaling events.
Specific Aim 1 will delineate the mechanism by which LRP1 deficiency inhibits adipocyte differentiation and promotes adipose dysfunction and inflammation, testing the hypothesis that constitutive PDGF receptor activation along with defective lysosomal enzyme processing and impaired autophagy due to LRP1 deficiency are responsible for these metabolic abnormalities.
Specific Aim 2 will test the hypothesis that adipocyte LRP1 deficiency exacerbates vascular occlusive diseases, including diet-induced atherosclerosis and injury-induced neointimal hyperplasia, despite its protection against diet-induced obesity and diabetes.
Specific Aim 3 will test the hypothesis that decreased HDL secretion and augmentation of injury-induced liver steatohepatitis observed with hepatic LRP1 deficiency are due to impaired lysosomal enzyme processing and autophagy and/or the reduced clearance of protease-protease inhibitor complexes. Taken together, these studies will clarify the beneficial versus adverse effects of adipose- and liver- specific LRP1 inactivation such that rational therapeutic recommendations can be made for metabolic and cardiovascular risk management.
Genetic association studies have identified polymorphisms of the LDL receptor related protein-1 (LRP1) as a risk factor for metabolic and cardiovascular diseases. This proposal will delineate the mechanism(s) by which LRP1 activities in adipose and liver modulate metabolic disease risk. The clinical implication of this mechanism-based study is that clarification of the beneficial versus adverse effects of adipose- and liver-LRP1 is necessary before any therapeutic recommendations for metabolic and cardiovascular risk management can be made.
|Hamlin, Allyson N; Chinnarasu, Sivaprakasam; Ding, Yinyuan et al. (2018) Low-density lipoprotein receptor-related protein-1 dysfunction synergizes with dietary cholesterol to accelerate steatohepatitis progression. J Biol Chem 293:9674-9684|
|Oldoni, Federico; van Capelleveen, Julian C; Dalila, Nawar et al. (2018) Naturally Occurring Variants in LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1) Affect HDL (High-Density Lipoprotein) Metabolism Through ABCA1 (ATP-Binding Cassette A1) and SR-B1 (Scavenger Receptor Class B Type 1) in Humans. Arterioscler Thromb Vasc Biol 38:1440-1453|
|Konaniah, Eddy S; Kuhel, David G; Basford, Joshua E et al. (2017) Deficiency of LRP1 in Mature Adipocytes Promotes Diet-Induced Inflammation and Atherosclerosis-Brief Report. Arterioscler Thromb Vasc Biol 37:1046-1049|
|Hamlin, Allyson N; Basford, Joshua E; Jaeschke, Anja et al. (2016) LRP1 Protein Deficiency Exacerbates Palmitate-induced Steatosis and Toxicity in Hepatocytes. J Biol Chem 291:16610-9|
|Hui, David Y (2016) Intestinal phospholipid and lysophospholipid metabolism in cardiometabolic disease. Curr Opin Lipidol 27:507-12|
|Yiew, Kan Hui; Chatterjee, Tapan K; Hui, David Y et al. (2015) Histone Deacetylases and Cardiometabolic Diseases. Arterioscler Thromb Vasc Biol 35:1914-9|
|Gadang, Vidya; Konaniah, Eddy; Hui, David Y et al. (2014) Mixed-lineage kinase 3 deficiency promotes neointima formation through increased activation of the RhoA pathway in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 34:1429-36|
|Omar, Abdullah; Chatterjee, Tapan K; Tang, Yaoliang et al. (2014) Proinflammatory phenotype of perivascular adipocytes. Arterioscler Thromb Vasc Biol 34:1631-6|
|Ulrich, Victoria; Konaniah, Eddy S; Lee, Wan-Ru et al. (2014) Antiphospholipid antibodies attenuate endothelial repair and promote neointima formation in mice. J Am Heart Assoc 3:e001369|
|Ulrich, Victoria; Konaniah, Eddy S; Herz, Joachim et al. (2014) Genetic variants of ApoE and ApoER2 differentially modulate endothelial function. Proc Natl Acad Sci U S A 111:13493-8|
Showing the most recent 10 out of 25 publications